Abstract
BackgroundPrevious reports of RAPID-PsA (NCT01087788) have demonstrated the clinical efficacy of certolizumab pegol (CZP) in patients (pts) with psoriatic arthritis (PsA) over 96 weeks (wks), but have not yet investigated...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have